In a significant move aimed at boosting the development of cell and gene therapies, Bionova Scientific, a part of the Asahi Kasei Group, has announced an ambitious $100 million investment. This investment will see the creation of a new state-of-the-art plasmid DNA (pDNA) production facility in The
In the rapidly-changing environment of the pharmaceutical industry, the innovative stride of Pharma 4.0 heralds a new era of drug production. This pivotal shift to smart manufacturing aligns with the principles of Industry 4.0, embedding digitalization and cutting-edge technology to meet the
In the dynamic realm of biopharmaceutical investments, the diverging analyst ratings for Can-Fite BioPharma (NYSE: CANF) underscore the complex calculus of betting on drug development firms. The stock analysis firm StockNews.com has planted its flag with a "hold" rating, signaling a cautious stance
AstraZeneca, the renowned pharmaceutical giant, has unveiled plans to invest $1.5 billion in a cutting-edge antibody drug conjugate (ADC) manufacturing facility in Singapore, marking a significant milestone in the company's history. The state-of-the-art factory is poised to become operational in
Novo Holdings, a prominent Danish investment firm with a focus on life sciences, has recently cemented its standing in the biopharma manufacturing industry through a strategic acquisition. Securing a majority stake in Single Use Support, Novo Holdings ventures further into an increasingly vital
EMA Fast-Tracks Approval for Adapted COVID-19 Variant Vaccines In an agile response to the rapidly mutating SARS-CoV-2 virus, the European Medicines Agency (EMA) has set forth new guidance to expedite the regulatory approval of COVID-19 vaccines modified to combat emerging variants. This move
